What is HC Wainwright’s Estimate for BHST Q1 Earnings?

BioHarvest Sciences Inc. (NASDAQ:BHST) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of BioHarvest Sciences in a research note issued on Tuesday, April 14th. HC Wainwright analyst A. Dayal anticipates that the company will post earnings per share of ($0.04) for the quarter. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.07 EPS and FY2028 earnings at $0.37 EPS.

A number of other research firms also recently weighed in on BHST. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a research note on Friday, March 27th. Roth Mkm assumed coverage on BioHarvest Sciences in a research note on Thursday, February 19th. They issued a “buy” rating and a $10.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $12.50.

BioHarvest Sciences Trading Down 0.7%

Shares of BHST stock opened at $4.27 on Thursday. The business’s 50 day moving average is $4.43 and its two-hundred day moving average is $6.23. BioHarvest Sciences has a twelve month low of $4.10 and a twelve month high of $12.80. The company has a market capitalization of $83.78 million, a P/E ratio of -7.00 and a beta of 1.16. The company has a current ratio of 3.97, a quick ratio of 3.38 and a debt-to-equity ratio of 0.10.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BHST. True North Advisors LLC increased its holdings in BioHarvest Sciences by 676.1% in the third quarter. True North Advisors LLC now owns 168,013 shares of the company’s stock valued at $1,581,000 after buying an additional 146,365 shares in the last quarter. King Luther Capital Management Corp purchased a new position in BioHarvest Sciences in the fourth quarter valued at about $208,000. Geode Capital Management LLC purchased a new position in BioHarvest Sciences in the fourth quarter valued at about $61,000. Thompson Siegel & Walmsley LLC purchased a new position in BioHarvest Sciences in the fourth quarter valued at about $1,945,000. Finally, HRT Financial LP purchased a new position in BioHarvest Sciences in the fourth quarter valued at about $75,000.

BioHarvest Sciences News Roundup

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: Analyst still models a return to profitability in the coming years — HC Wainwright forecasts positive EPS of $0.07 in FY2027 and $0.37 in FY2028 (and $0.80 in FY2029), signaling an eventual recovery from current losses. This provides a constructive narrative for longer-term investors if the company hits growth/margin targets. MarketBeat Report
• Neutral Sentiment: HC Wainwright laid out detailed near-term estimates: Q1 2026 EPS -$0.04, Q2 -$0.09, Q3 -$0.05, Q4 -$0.04 and FY2026 EPS -$0.22. Those quarterly figures imply the company remains loss-making through FY2026 but with a smaller FY2026 loss than the consensus full-year estimate of -$0.80, which may reduce downside vs. market expectations if results align. MarketBeat Report
• Negative Sentiment: HC Wainwright cut its prior long-term targets — FY2027 was trimmed from $0.22 to $0.07, FY2028 from $0.55 to $0.37 and FY2029 from $1.00 to $0.80. Those downward revisions reduce implied upside and suggest the analyst sees slower margin expansion or revenue growth than previously expected, a likely catalyst for selling pressure. MarketBeat Report

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.